Navigation Links
Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint

y not warrant further development of this compound for the treatment of chronic hepatitis B and completing our clinical studies may take longer or cost more than expected. In addition, feedback from regulatory authorities or results from clinical trials might require modifications or delays in later stage clinical trials or additional trials to be performed. Further, the FDA and other regulatory authorities may not approve tenofovir DF for the treatment of chronic hepatitis B, and marketing approval, if granted, may have significant limitations on its use and physicians and may not see advantages of tenofovir DF over other treatment options and may therefore be reluctant to prescribe tenofovir DF for chronic hepatitis B. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in Gilead's Annual Report on Form 10-K for the year ended December 31, 2006 and its Quarterly Report on Form 10-Q for the first quarter of 2007, filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.

Hepsera and Viread are registered trademarks of Gilead Sciences, Inc.

For more information on Gilead, please call the Gilead Public Affairs Department at 1-800-GILEAD-5 (1-800-445-3235) or visit www.gilead.com.


CONTACT: Gilead Sciences, Inc.
Susan Hubbard, 650-522-5715 (Investors)
James Loduca, 650-522-5908 (Media)
www.gilead.com

SOURCE: Gilead Sciences, Inc.



'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
2. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
3. Second Successful Quigley QR-443 Study Suggests Method of Action Relevant to Broad Range of Chronic Inflammatory Diseases - Human Study to Follow -
4. NeurogesX Announces Presentation of Positive Phase 3 Clinical Data at the Second International Congress on Neuropathic Pain Meeting (NeuPSIG)
5. Repros Androxal Shows Highly Statistically Significant Positive Effects in Men with Secondary Hypogonadism
6. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
7. Positive Results for Second-Generation Taxus Liberte Coronary Stent System Highlighted in Journal of American College of Cardiology
8. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
9. Gilead Announces Achievement of Primary Efficacy Endpoint in Second Phase III Study of Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis
10. Amlodipine and Olmesartan Study Results Released;Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
11. Amlodipine and Olmesartan Study Results Released; Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
Post Your Comments:
(Date:9/17/2014)... EMERYVILLE, Calif. , Sept. 17, 2014 /PRNewswire/ ... newest data analytics solution that brings complete visibility ... minimize risks in an ever-evolving reimbursement landscape. Powered ... Integrity brings transparency to the critical point between ... operations impact revenue. The solution will improve revenue ...
(Date:9/17/2014)... MADISON, Tenn. , Sept. 17, 2014 ... be; these infections are not only uncomfortable, they,re often ... best-laid social plans. pH-D Feminine Health Support ( http://ph-defense.com ... vaginal health. It is an all-natural, homeopathic product. ... the most common symptoms of vaginal infection. In many ...
(Date:9/17/2014)... , Sept. 17, 2014  Aratana Therapeutics, Inc. ... company focused on licensing, developing and commercializing innovative ... pricing of its public offering of 4,500,000 shares of its ... of $9.25 per share. Aratana has granted the ... an additional 675,000 shares of its common stock. ...
Breaking Medicine Technology:MedeAnalytics Unveils New Revenue Integrity Solution to Support the Transition to Value-Based Healthcare 2MedeAnalytics Unveils New Revenue Integrity Solution to Support the Transition to Value-Based Healthcare 3New Product from Vireo Systems: pH-D Feminine Health Support 2Aratana Therapeutics, Inc. Announces Pricing of Public Offering 2
... DELAND, Fla., May 13 USHIFU, LLC, the clinical ... pleased,to announce conditional written approval pending minor changes to ... for the treatment of,recurrent prostate cancer with the Sonablate(R) ... Dr. Herbert Lepor, Chairman of Urology at NYU ...
... Products Expand Infection Prevention Business, DUBLIN, Ohio, ... products and services that improve the safety and,productivity ... the,acquisition of assets of privately held Enturia, Inc., ... ChloraPrep(R) brand name., ChloraPrep(R) brand products are ...
Cached Medicine Technology:FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer 2Cardinal Health Completes Enturia Acquisition 2
(Date:9/17/2014)... (PRWEB) September 17, 2014 Wright ... Conserve line of metal-on-metal hip replacements continue to ... U.S. District Court, Northern District of Georgia, Bernstein ... List issued by the U.S. Judicial Panel on ... 397 product liability claims have been filed in ...
(Date:9/17/2014)... TX (PRWEB) September 17, 2014 Smart ... Editor’s Picks by Progressive Grocer, a leading trade magazine ... was awarded for originality and flavor, among other attributes. ... as an Editor’s Pick in the September print issue ... Grocer website. , The pizza won based on its ...
(Date:9/17/2014)... Suwanee, GA (PRWEB) September 17, 2014 ... proud to announce the launch of its new vegan ... mask is extremely effective and provided the results skincare ... was to create a gentle yet active mask that ... CEO Lake Louise.” , This Sugar Cane Fruit Mask ...
(Date:9/17/2014)... -- Present-day Europeans are the descendants of at ... a new study. Previous research suggested ... European farmers. But, a new genetic analysis involving ... descendants of Ancient North Eurasians. Nearly all present-day ... group, researchers from Harvard Medical School said. , ...
(Date:9/17/2014)... HealthDay Reporter WEDNESDAY, ... who turn to artificial sweeteners to soothe their sweet ... new Israeli study suggests. Artificial sweeteners can potentially ... researchers found in human and mouse studies. That,s ... bacteria residing in the intestines in ways that can ...
Breaking Medicine News(10 mins):Health News:Wright Hip Lawsuit News: Nearly 400 Filings Reported in Federal Wright Conserve Hip Replacement Litigation, Bernstein Liebhard LLP Reports 2Health News:Wright Hip Lawsuit News: Nearly 400 Filings Reported in Federal Wright Conserve Hip Replacement Litigation, Bernstein Liebhard LLP Reports 3Health News:Smart Flour Foods Wins 2014 Progressive Grocer Editor’s Pick Award 2Health News:EcoBeauty Brand Lotus Moon Unveils New Gluten-Free Sugar Cane Fruit Mask 2Health News:Europeans Are Descendants of at Least 3 Ancient Human Groups: Study 2Health News:Europeans Are Descendants of at Least 3 Ancient Human Groups: Study 3Health News:Artificial Sweeteners May Raise Blood Sugar Levels: Study 2Health News:Artificial Sweeteners May Raise Blood Sugar Levels: Study 3
... in what triggers jealousy in men and women, study finds ... in the eye of the beholder, a new study suggests. ... to men while emotional infidelity may be of greater concern ... experiences in previous relationships may be even more important. , ...
... notes bloating, stomach pain, fatigue also point to less ... Relying on symptoms alone to identify women who have ... early, a new study indicates. , Research shows that ... healthy women to report symptoms such as abdominal pain, ...
... Jan. 28 Baylor Sammons Breast Center at ... has been recognized by the National Accreditation Program for Breast ... every significant advantage in their battle against breast disease." The ... NAPBC. Accreditation by the NAPBC is only given to those ...
... , ST. PAUL, Minn. , Jan. 28 ... -based Campbell Mithun, has been named Event Chair for this year’s ... Minnesota’s only nonprofit organization to supply life-saving blood and blood components ... to have Jeff Naughtin on board to head this ...
... , TORRANCE, Calif. , Jan. 28 ... is often a renewed focus on personal health and nutrition. ... year are prebiotics and immune health. This is welcome news ... addresses both categories. , SPINS, the leading provider of ...
... past or future, study finds , THURSDAY, Jan. 28 (HealthDay ... look toward the future, their body language reflects their sense ... the University of Aberdeen fitted subjects with motion sensors and ... past. The bodies of those who thought about the future ...
Cached Medicine News:Health News:Personal History Linked to Feelings of Betrayal 2Health News:Symptoms Alone Don't Spot Ovarian Cancer Early 2Health News:Symptoms Alone Don't Spot Ovarian Cancer Early 3Health News:Breast Center at Baylor Dallas Recognized for Commitment to Fighting Breast Disease 2Health News:Breast Center at Baylor Dallas Recognized for Commitment to Fighting Breast Disease 3Health News:Memorial Blood Centers Names Campbell Mithun’s Jeff Naughtin Event Chair for What’s Your Type? Benefit 2Health News:Memorial Blood Centers Names Campbell Mithun’s Jeff Naughtin Event Chair for What’s Your Type? Benefit 3Health News:Sun Chlorella USA Positioned for Strong 2010 2
... Digital Wide Field Lens combines ... high magnification. The enhanced double ... provide high resolution stereo views ... reflections. These unique features make ...
... Stereo Fundus Lens is specifically designed for ... retina. Its enhanced 3-D stereoscopic design enables ... detail, making it ideal for detecting changes ... serous detachments and other macular abnormalities. It ...
The Pan Retinal® 2.2 uniquely combines magnification nearly that of the 20D lens with a field of view approaching that of the 30D lens. Excellent for virtually every examination procedure, includ...
... Volks state-of-the-art 20D diagnostic/laser lens ... astigmatic aberrations and coma delivering ... 20 diopter lens on the market. ... maintains linear image magnification and perfect ...
Medicine Products: